Arrowstreet Capital
TRDA icon

Arrowstreet Capital’s Entrada Therapeutics TRDA Stock Holding History

Arrowstreet Capital’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-102,008
Closed -$685K – 2112
2025
Q2 		$685K Sell
102,008
-21,890
-18% -$176K ﹤0.01% 1684
2025
Q1 		$1.12M Sell
123,898
-98,622
-44% -$1.23M ﹤0.01% 1447
2024
Q4 		$3.85M Buy
222,520
+122,823
+123% +$2.23M ﹤0.01% 1078
2024
Q3 		$1.59M Buy
99,697
+85,390
+597% +$1.35M ﹤0.01% 1283
2024
Q2 		$204K Hold
14,307
– – ﹤0.01% 1445
2024
Q1 		$203K Buy
+14,307
New +$202K ﹤0.01% 1580

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Arrowstreet Capital's TRDA Position: Q3 2025 in Review

Arrowstreet Capital sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 102,008 shares — an estimated $685K sold.

Arrowstreet Capital first reported a position in TRDA in Q1 2024 and held it in 6 quarters. The position peaked at $3.85M in Q4 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Arrowstreet Capital reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Arrowstreet Capital sold 102,008 Entrada Therapeutics shares in Q3 2025, an estimated $685K.
  • Arrowstreet Capital first reported a position in Entrada Therapeutics in Q1 2024 and held it in 6 quarters.
  • Arrowstreet Capital's Entrada Therapeutics position peaked at $3.85M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Arrowstreet Capital's 13F filing for Q3 2025, filed 13 Nov 2025.